Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of oral cladribine in relapsing-remitting multiple sclerosis (post-CLARITY)
2007-000381-20Phase 3Completed
- Sponsor
- Merck Serono
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Oral cladribine with Placebo (2 arms). Primary endpoint: Long-term safety of oral cladribine. Started Oct 2007; status: completed.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2007-000381-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000381-20.